Preview

Остеопороз и остеопатии

Расширенный поиск

ПРИВЕРЖЕННОСТЬ К ЛЕЧЕНИЮ ОСТЕОПОРОЗА: ВОПРОСПЕРЕНОСИМОСТИ, РЕЖИМА ЛЕЧЕНИЯИЛИ ИСКЛЮЧИТЕЛЬНО ХОРОШЕГО ДИАЛОГА С ПАЦИЕНТОМ?

https://doi.org/10.14341/osteo2010342-49

Полный текст:

Аннотация

Good antifracture treatment efficacy requires adherence,
which is often suboptimal. The most common reason for
nonadherence is real or perceived intolerance to the medication.
Although dosage frequency plays a significant role,
pharmacokinetics is but one of many barriers to adherence.
Patient-related factors are an important consideration, but a good
doctor-patient relationship with clear communication can enable
patients to make more-informed choices when deciding their
treatment. It is possible to improve adherence, but a multimodal
approach is needed to achieve this aim.

Список литературы

1. EFFO and NOF Consensus Development Statement. Who are candidates for prevention and treatment for osteoporosis? Osteoporos Int. 1997;7:1-6.

2. Johnell O, Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-1733.

3. Sambrook P. Compliance with treatment in osteoporosis patients-an ongoing problem. Aust Fam Physician. 2006;35:135-137.

4. NICE. Osteoporosis: assessment of fracture risk and the prevention of osteoporotic fractures in individuals at high risk. 2008. http://www.nice. org.uk/nice media/pdf/OsteoporosisEvidenceReviews190908.pdf

5. Kanis JA, Oden A, Johansson H, Borgström F, Ström O, McCloskey E. FRAX and its applications to clinical practice. Bone. 2009:44:734-743.

6. Kothawala R, Badamgarav E, Ryu S, Miller RM, Halbert RJ. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc. 2007;82:1493-1501.

7. Seeman E, Compston J, Adachi J, et al. Non-compliance: the Achilles' heel of anti-fracture efficacy. Osteoporos Int. 2007;18:711-719.

8. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin. 2005;21:1453-1460.

9. Rabenda V, Mertens R, Fabri V, et al. Adherence to bisphosphonates therapy and hip fracture risk in osteoporotic women. Osteoporos Int. 2008;19:48 811-818.

10. Huybrechts KF, Ishak KJ, Caro JJ. Assessment of compliance with osteoporosis treatment and its consequences in a managed care population. Bone. 2006;38:922-928.

11. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006;81: 1013-1022.

12. Gallagher AM, Rietbrock S, Olson M, van Staa TP. Fracture outcomes related to persistence and compliance with oral bisphosphonates. J Bone Miner Res. 2008;23:1569-1575.

13. Sebaldt RJ, Shane LG, Pham B, Cook R, Thabane L, Petrie A. Long term effectiveness outcomes of non-compliance and non-persistence with daily regimen bisphosphonate therapy in patients with osteoporosis treated in tertiary specialist care. Osteoporos Int. 2004;15:S107.

14. Toteston AN, Grove MR, Hammond CS, et al. Early discontinuation of treatment for osteoporosis. Am J Med. 2003;15:209-216.

15. Lau E, Papaioannou A, Dolovich L, et al. Patients' adherence to osteoporosis therapy. Exploring the perceptions of postmenopausal women. Can Fam Physician. 2008;54:394-402.

16. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate. The Fracture Interventional Trial. Arch Intern Med. 2000;160: 517-525.

17. Cryer B, Bauer DC. Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc. 2002;77:1031-1043.

18. Greenspan S, Field-Munves E, Tonino R, et al. Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebocontrolled study. Mayo Clin Proc. 2002;77:1044-1052.

19. Strampel W, Emkey R, Civitelli R. Safety considerations with bisphosphonates for the treatment of osteoporosis. Drug Safety. 2007;30:755-763.

20. Recker RR, Lewiecki M, Miller PD, Reiffel J. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009;122:S22-S32.

21. Stevenson M, Lloyd-Jones M, Nigris ED, Brewer N, Davis S, Oakley J. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis. Health Technol Assess. 2005;9(22).

22. Hamilton B, McCoy K, Taggart H. Tolerability and compliance with risedronate in clinical practice. Osteoporos Int. 2003;14:259-262.

23. Miller PD, Woodson G, Licata AA, et al. Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther. 2000;22:1433-1442.

24. Lindsay R, Cosman F, Lobo RA, et al. Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab. 1999;84:3076-3081.

25. Joint Formulary Committee. British National Formulary. 57th ed. London, UK: British Medical Association and Royal Pharmaceutical Society of Great Britain; 2009.

26. Reid IR. Osteonecrosis of the jaw-who gets it, and why? Bone. 2009;44: 4-10.

27. Silverman SL, Landersberg R. Osteonecrosis of the jaw and the role of bisphosphonates: a critical review. Am J Med. 2009;122:S33-S45.

28. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42:841-847.

29. Black DM, Delmas PD, Eastell R; for the HORIZON Pivotal Fracture Trial Group. Once-yearly zoledronic acid 5mg for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.

30. Felsenberg D, Hoffmeister B, Amling M, et al. Kiefernekrosen nach hoch dosierter Bisphosphonattherapie. Dtsch Arztebl. 2006;103:3078-3081.

31. Mavrokokki A, Cheng A, Stein B, Goss AN. The nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg. 2007;65:415-423.

32. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-468.

33. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab. 2005;90:2816-2822.

34. Stevenson M, Davis S, Lloyd-Jones M, Beverley C. The clinical effectiveness and cost-effectiveness of strontium ranelate for the prevention of osteoporotic fragility fractures in postmenopausal women. Health Technol Assess. 2007;11(4).

35. O'Donnell S, Cranney A, Wells GA, Adachi J, Reginster JY. Strontium ranelate for preventing and treating postmenopausal osteoporosis (Review). Cochrane Database of Systematic Reviews. 2006;issue 4.

36. Pernicova I, Middleton ET, Aye M. Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert. Osteoporos Int. 2008;19:1811-1812. Letter.

37. European Public Assessment Reports (EPARs) for authorised medicinal products for human use. Protelos. 2007. Press Release. Available at http://www. emea.europa.eu/humandocs/PDFs/EPAR/protelos/ PressRelease_Protelos_ 41745807en.pdf

38. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in ostmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282:637-645.

39. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321- 333.

40. Col NF, Bowlby LA, McGarry K. The role of menopausal hormone therapy in preventing osteoporotic fractures: a critical review of the clinical evidence. Minnerva Med. 2005;96:331-342.

41. Compston J. How to manage osteoporosis after the menopause. Best Pract Res Clin Rheumatol. 2005;19:1007-1019.

42. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359:697-708.

43. Simon JA, Lewiecki EM, Smith ME, Petruschke RA, Wang L, Palmisano JJ. Patient preference for once-weekly alendronate 70mg versus once-daily alendronate 10mg: a multicenter, randomized, open-label, crossover study. Clin Ther. 2002;24:1871-1886.

44. Kendler D, Kung AW, Fuleihan Gel-H, et al. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate. Maturitas. 2004;48:243-251.

45. Richards JB, Cherkas LF, Spector TD. An analysis of which anti-osteoporosis therapeutic regimen would improve compliance in a population of elderly adults. Curr Med Res Opin. 2007;23:293-299.

46. Weiss TW, McHorney CA. Osteoporosis medication profile preference: results from the PREFER-US study. Health Expectations. 2007;10:211-223.

47. Fraenkel L, Gulanski B, Wittink D. Patient treatment preferences for osteoporosis. Arthritis Rheum. 2006;55:729-735.

48. Segal E, Tamir A, Ish-Shalom S. Compliance of osteoporotic patients with different treatment regimens. IMAJ. 2003;5:859-862.

49. Jamal SA, Ridout R, Chase C, Fielding L, Rubin LA, Hawker GA. Bone mineral density testing and osteoporosis education improve lifestyle behaviors in premenopausal women: a prospective study. J Bone Miner Res. 1999;14: 2143-2149.

50. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medications. Arch Intern Med. 2005;165:2414-2419.

51. Bergmann P, Body JJ, Boonen S, et al; Members of Advisory Board on Bone Markers. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of biphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. Int J Clin Pract. 2009;63:19-26.

52. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353: 487-497.

53. Harrington JT, Barash HL, Day S, Lease J. Redesigning the care of fragility fracture patients to improve osteoporosis management: a health care improvement project. Arthr Rheum. 2005;53:198-204.

54. Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004;89:1117-1123.


Рецензия

Для цитирования:


., ., ., . ПРИВЕРЖЕННОСТЬ К ЛЕЧЕНИЮ ОСТЕОПОРОЗА: ВОПРОСПЕРЕНОСИМОСТИ, РЕЖИМА ЛЕЧЕНИЯИЛИ ИСКЛЮЧИТЕЛЬНО ХОРОШЕГО ДИАЛОГА С ПАЦИЕНТОМ? Остеопороз и остеопатии. 2010;13(3):42-49. https://doi.org/10.14341/osteo2010342-49

For citation:


FANG E.S., SPEKTOR T.D., FUNG E.C., SPECTOR T.D. PRIVERZhENNOST' K LEChENIYu OSTEOPOROZA: VOPROSPERENOSIMOSTI, REZhIMA LEChENIYaILI ISKLYuChITEL'NO KhOROShEGO DIALOGA S PATsIENTOM? Osteoporosis and Bone Diseases. 2010;13(3):42-49. (In Russ.) https://doi.org/10.14341/osteo2010342-49

Просмотров: 174


ISSN 2072-2680 (Print)
ISSN 2311-0716 (Online)